Sergiy Kyryachenko1, Adrien Georges1, Mengyao Yu1, Takiy Barrandou1, Lilong Guo2,3, Patrick Bruneval1, Tony Rubio4,5, Judith Gronwald4,5, Hassina Baraki6,5, Ingo Kutschka6,5, Kedar K Aras7, Igor R Efimov7, Russel A Norris2,3, Niels Voigt4,5,8, Nabila Bouatia-Naji1. 1. Université de Paris, PARCC, Inserm, France (S.K., A.G., M.Y., T.B., P.B., N.B.-N.). 2. Department of Regenerative Medicine and Cell Biology (L.G., R.A.N.), Medical University of South Carolina, Charleston. 3. Department of Medicine (L.G., R.A.N.), Medical University of South Carolina, Charleston. 4. Institute of Pharmacology and Toxicology (T.R., J.G., N.V.), University Medical Center Göttingen, Germany. 5. DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Germany (T.R., J.G., H.B., I.K., N.V.). 6. Department of Thoracic and Cardiovascular Surgery (H.B., I.K.), University Medical Center Göttingen, Germany. 7. Department of Biomedical Engineering, George Washington University, Washington, DC (K.K.A., I.R.E.). 8. Cluster of Excellence Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells (MBExC), University of Göttingen, Germany (N.V.).
Abstract
RATIONALE: Mitral valve prolapse (MVP) is a common valvopathy that leads to mitral insufficiency, heart failure, and sudden death. Functional genomic studies in mitral valves are needed to better characterize MVP-associated variants and target genes. OBJECTIVE: To establish the chromatin accessibility profiles and assess functionality of variants and narrow down target genes at MVP loci. METHODS AND RESULTS: We mapped the open chromatin regions in nuclei from 11 human pathogenic and 7 nonpathogenic mitral valves by an assay for transposase-accessible chromatin with high-throughput sequencing. Open chromatin peaks were globally similar between pathogenic and nonpathogenic valves. Compared with the heart tissue and cardiac fibroblasts, we found that MV-specific assay for transposase-accessible chromatin with high-throughput sequencing peaks are enriched near genes involved in extracellular matrix organization, chondrocyte differentiation, and connective tissue development. One of the most enriched motifs in MV-specific open chromatin peaks was for the nuclear factor of activated T cells family of TFs (transcription factors) involved in valve endocardial and interstitial cell formation. We also found that MVP-associated variants were significantly enriched (P<0.05) in mitral valve open chromatin peaks. Integration of the assay for transposase-accessible chromatin with high-throughput sequencing data with risk loci, extensive functional annotation, and gene reporter assay suggest plausible causal variants for rs2641440 at the SMG6/SRR locus and rs6723013 at the IGFBP2/IGFBP5/TNS1 locus. CRISPR-Cas9 deletion of the sequence including rs6723013 in human fibroblasts correlated with increased expression only for TNS1. Circular chromatin conformation capture followed by high-throughput sequencing experiments provided evidence for several target genes, including SRR, HIC1, and DPH1 at the SMG6/SRR locus and further supported TNS1 as the most likely target gene on chromosome 2. CONCLUSIONS: Here, we describe unprecedented genome-wide open chromatin profiles from human pathogenic and nonpathogenic MVs and report specific gene regulation profiles, compared with the heart. We also report in vitro functional evidence for potential causal variants and target genes at MVP risk loci involving established and new biological mechanisms. Graphic Abstract: A graphic abstract is available for this article.
RATIONALE: Mitral valve prolapse (MVP) is a common valvopathy that leads to mitral insufficiency, heart failure, and sudden death. Functional genomic studies in mitral valves are needed to better characterize MVP-associated variants and target genes. OBJECTIVE: To establish the chromatin accessibility profiles and assess functionality of variants and narrow down target genes at MVP loci. METHODS AND RESULTS: We mapped the open chromatin regions in nuclei from 11 human pathogenic and 7 nonpathogenic mitral valves by an assay for transposase-accessible chromatin with high-throughput sequencing. Open chromatin peaks were globally similar between pathogenic and nonpathogenic valves. Compared with the heart tissue and cardiac fibroblasts, we found that MV-specific assay for transposase-accessible chromatin with high-throughput sequencing peaks are enriched near genes involved in extracellular matrix organization, chondrocyte differentiation, and connective tissue development. One of the most enriched motifs in MV-specific open chromatin peaks was for the nuclear factor of activated T cells family of TFs (transcription factors) involved in valve endocardial and interstitial cell formation. We also found that MVP-associated variants were significantly enriched (P<0.05) in mitral valve open chromatin peaks. Integration of the assay for transposase-accessible chromatin with high-throughput sequencing data with risk loci, extensive functional annotation, and gene reporter assay suggest plausible causal variants for rs2641440 at the SMG6/SRR locus and rs6723013 at the IGFBP2/IGFBP5/TNS1 locus. CRISPR-Cas9 deletion of the sequence including rs6723013 in human fibroblasts correlated with increased expression only for TNS1. Circular chromatin conformation capture followed by high-throughput sequencing experiments provided evidence for several target genes, including SRR, HIC1, and DPH1 at the SMG6/SRR locus and further supported TNS1 as the most likely target gene on chromosome 2. CONCLUSIONS: Here, we describe unprecedented genome-wide open chromatin profiles from human pathogenic and nonpathogenic MVs and report specific gene regulation profiles, compared with the heart. We also report in vitro functional evidence for potential causal variants and target genes at MVP risk loci involving established and new biological mechanisms. Graphic Abstract: A graphic abstract is available for this article.
Entities:
Keywords:
chromatin; extracellular matrix; fibroblast; genome wide association studies; mitral valve prolapse; single nucleotide polymorphism
Authors: Owen W J Prall; Mary K Menon; Mark J Solloway; Yusuke Watanabe; Stéphane Zaffran; Fanny Bajolle; Christine Biben; Jim J McBride; Bronwyn R Robertson; Hervé Chaulet; Fiona A Stennard; Natalie Wise; Daniel Schaft; Orit Wolstein; Milena B Furtado; Hidetaka Shiratori; Kenneth R Chien; Hiroshi Hamada; Brian L Black; Yumiko Saga; Elizabeth J Robertson; Margaret E Buckingham; Richard P Harvey Journal: Cell Date: 2007-03-09 Impact factor: 41.582
Authors: Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén Journal: Science Date: 2015-01-23 Impact factor: 47.728
Authors: Ming Fang; Christina M Alfieri; Alexia Hulin; Simon J Conway; Katherine E Yutzey Journal: Arterioscler Thromb Vasc Biol Date: 2014-10-23 Impact factor: 8.311
Authors: Leslie A Frieden; Todd A Townsend; David B Vaught; Daniel M Delaughter; Yoonha Hwang; Joey V Barnett; Jin Chen Journal: Dev Dyn Date: 2010-10-19 Impact factor: 3.780
Authors: Mengyao Yu; Sergiy Kyryachenko; Stephanie Debette; Philippe Amouyel; Jean-Jacques Schott; Thierry Le Tourneau; Christian Dina; Russell A Norris; Albert A Hagège; Xavier Jeunemaitre; Nabila Bouatia-Naji Journal: Circ Genom Precis Med Date: 2021-08-31
Authors: Mengyao Yu; Catherine Tcheandjieu; Adrien Georges; Ke Xiao; Helio Tejeda; Christian Dina; Thierry Le Tourneau; Madalina Fiterau; Renae Judy; Noah L Tsao; Dulguun Amgalan; Chad J Munger; Jesse M Engreitz; Scott M Damrauer; Nabila Bouatia-Naji; James R Priest Journal: JCI Insight Date: 2022-02-08
Authors: Aeilko H Zwinderman; Vivian de Waard; Mitzi M van Andel; Maarten Groenink; Maarten P van den Berg; Janneke Timmermans; Arthur J H A Scholte; Barbara J M Mulder Journal: Clin Epigenetics Date: 2021-12-11 Impact factor: 6.551